{"id":45355,"date":"2022-06-22T14:01:44","date_gmt":"2022-06-22T12:01:44","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/comera-life-sciences-announces-issuance-of-u-s-patent-for-proprietary-excipients-in-sqore-platform\/"},"modified":"2022-06-22T14:01:44","modified_gmt":"2022-06-22T12:01:44","slug":"comera-life-sciences-announces-issuance-of-u-s-patent-for-proprietary-excipients-in-sqore-platform","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/comera-life-sciences-announces-issuance-of-u-s-patent-for-proprietary-excipients-in-sqore-platform\/","title":{"rendered":"Comera Life Sciences Announces Issuance of U.S. Patent for Proprietary Excipients in SQore Platform"},"content":{"rendered":"
\n

WOBURN, Mass.–(BUSINESS WIRE)–Comera Life Sciences Holdings, Inc.<\/a> (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, expanded its patent portfolio with the issuance of U.S. Patent No. 11,357,857 (the \u2018857 patent), which provides Comera exclusive rights pertaining to certain excipients in its SQore\u2122 platform as viscosity-lowering agents to significantly optimize filtration efficiency of protein solutions during the biologics manufacturing process. The \u2018857 patent reflects a significant addition to Comera\u2019s current intellectual property portfolio and expands the potential commercial applications of SQore, broadening patent protections beyond use in therapeutic antibody formulations to include manufacturing process enhancement.\n<\/p>\n

<\/a><\/p>\n

\n\u201cWe believe that the \u2018857 patent will more broadly protect SQore\u2019s use in manufacturing process optimization and has the potential of expanding SQore\u2019s commercial value in biologic manufacturing, as we work with our strategic partners to transform the delivery of biologics to benefit patient care,\u201d said Jeff Hackman, Chief Executive Officer and Chairman of Comera. \u201cWe have been significantly investing in the scientific development of our SQore platform, and today\u2019s patent issuance reflects our efforts to strengthen our intellectual property position for SQore.\u201d\n<\/p>\n

\nFiltration of protein solutions is a key component of the antibody manufacturing process and is utilized for sterilization, removal of impurities, and concentration of the active ingredient to allow for use as an injected medicine. The filtration steps can be time consuming, costly, and inefficient, and an increase in filtration rate could improve the economics of production. Comera believes that its SQore technology, by lowering viscosity of high concentration protein solutions, allows for high-throughput filtration and a significantly more efficient manufacturing process.\n<\/p>\n

\n\u201cThe benefits of Comera\u2019s viscosity-reducing SQore technology goes well-beyond enabling subcutaneous drug formulations,\u201d said Alan Herman, Ph.D., a scientific advisor to Comera and former Chief Scientific Officer of Coherus Biosciences. \u201cHigh viscosity encountered during the downstream processing phase of drug manufacturing can significantly reduce efficiency, so technologies like SQore that can lower viscosity offer the potential to greatly optimize production throughput of antibody formulations.\u201d\n<\/p>\n

\nAbout Comera Life Sciences<\/b>\n<\/p>\n

\nLeading a compassionate new era in medicine, Comera Life Sciences is applying a deep knowledge of formulation science and technology to transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms. The goal of this approach is to provide patients with the freedom of self-injectable care, reduce institutional dependency and to put patients at the center of their treatment regimen.\n<\/p>\n

\nTo learn more about the Comera Life Sciences mission, as well as the proprietary SQore\u2122 platform, visit https:\/\/comeralifesciences.com\/<\/a>.\n<\/p>\n

\nForward-Looking Statements<\/b>\n<\/p>\n

\nThis press release contains includes \u201cforward-looking statements\u201d within the meaning of the federal securities laws. These forward-looking statements generally are identified by the words \u201cbelieve,\u201d \u201cproject,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cestimate,\u201d \u201cintend,\u201d \u201cstrategy,\u201d \u201cfuture,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cmay,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d \u201cwill be,\u201d \u201cwill continue,\u201d \u201cwill likely result,\u201d and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including, but not limited to: risks that the recently completed business combination disrupts the Company\u2019s current plans and ability to retain its employees; the Company\u2019s ability to maintain the listing of its securities on the Nasdaq Capital Market; the effect of the COVID-19 pandemic on the Company\u2019s business; the price of the Company\u2019s securities may be volatile due to a variety of factors, including changes in the competitive and highly regulated industries in which the Company plans to operate, variations in performance across competitors, changes in laws and regulations affecting the Company\u2019s business and changes in the capital structure; the ability to implement business plans, forecasts, and other expectations and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which the Company operates; the risk that the Company and its current and future collaborators are unable to successfully develop and commercialize the Company\u2019s products or services, or experience significant delays in doing so; the risk that we will be unable to continue to attract and retain third-party collaborators, including collaboration partners and licensors; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that the Company is unable to secure or protect its intellectual property; the risk that the Company is unable to secure regulatory approval for its product candidates; general economic conditions; and other risks and uncertainties indicated in the Current Report on Form 8-K filed with the SEC on May 25, 2022 under \u201cRisk Factors\u201d and in other filings that have been made or will be made with the SEC. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the \u201cRisk Factors\u201d section of Comera\u2019s Current Report on Form 8-K filed with the SEC on May 25, 2022 and other documents filed by Comera from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Comera assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Comera can give no assurance that it will achieve its expectations.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nComera Investor<\/b>
John Woolford
\n
ICR Westwicke
\n
John.Woolford@westwicke.com<\/a>\n<\/p>\n

\nComera Press<\/b>
Karen Chase
\n
ICR Westwicke
\n
Karen.Chase@westwicke.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

WOBURN, Mass.–(BUSINESS WIRE)–Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, expanded its patent portfolio with the issuance of U.S. Patent No. 11,357,857 (the \u2018857 patent), which provides Comera exclusive rights pertaining to certain excipients in its SQore\u2122 … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-45355","6":"format-standard","7":"category-industry"},"yoast_head":"\nComera Life Sciences Announces Issuance of U.S. Patent for Proprietary Excipients in SQore Platform - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/comera-life-sciences-announces-issuance-of-u-s-patent-for-proprietary-excipients-in-sqore-platform\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Comera Life Sciences Announces Issuance of U.S. Patent for Proprietary Excipients in SQore Platform - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"WOBURN, Mass.–(BUSINESS WIRE)–Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, expanded its patent portfolio with the issuance of U.S. Patent No. 11,357,857 (the \u2018857 patent), which provides Comera exclusive rights pertaining to certain excipients in its SQore\u2122 ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/comera-life-sciences-announces-issuance-of-u-s-patent-for-proprietary-excipients-in-sqore-platform\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-22T12:01:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220621006060\/en\/1493063\/21\/comera_logo_rgb.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/comera-life-sciences-announces-issuance-of-u-s-patent-for-proprietary-excipients-in-sqore-platform\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/comera-life-sciences-announces-issuance-of-u-s-patent-for-proprietary-excipients-in-sqore-platform\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Comera Life Sciences Announces Issuance of U.S. Patent for Proprietary Excipients in SQore Platform\",\"datePublished\":\"2022-06-22T12:01:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/comera-life-sciences-announces-issuance-of-u-s-patent-for-proprietary-excipients-in-sqore-platform\\\/\"},\"wordCount\":1029,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/comera-life-sciences-announces-issuance-of-u-s-patent-for-proprietary-excipients-in-sqore-platform\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220621006060\\\/en\\\/1493063\\\/21\\\/comera_logo_rgb.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/comera-life-sciences-announces-issuance-of-u-s-patent-for-proprietary-excipients-in-sqore-platform\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/comera-life-sciences-announces-issuance-of-u-s-patent-for-proprietary-excipients-in-sqore-platform\\\/\",\"name\":\"Comera Life Sciences Announces Issuance of U.S. Patent for Proprietary Excipients in SQore Platform - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/comera-life-sciences-announces-issuance-of-u-s-patent-for-proprietary-excipients-in-sqore-platform\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/comera-life-sciences-announces-issuance-of-u-s-patent-for-proprietary-excipients-in-sqore-platform\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220621006060\\\/en\\\/1493063\\\/21\\\/comera_logo_rgb.jpg\",\"datePublished\":\"2022-06-22T12:01:44+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/comera-life-sciences-announces-issuance-of-u-s-patent-for-proprietary-excipients-in-sqore-platform\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/comera-life-sciences-announces-issuance-of-u-s-patent-for-proprietary-excipients-in-sqore-platform\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/comera-life-sciences-announces-issuance-of-u-s-patent-for-proprietary-excipients-in-sqore-platform\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220621006060\\\/en\\\/1493063\\\/21\\\/comera_logo_rgb.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220621006060\\\/en\\\/1493063\\\/21\\\/comera_logo_rgb.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/comera-life-sciences-announces-issuance-of-u-s-patent-for-proprietary-excipients-in-sqore-platform\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Comera Life Sciences Announces Issuance of U.S. Patent for Proprietary Excipients in SQore Platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Comera Life Sciences Announces Issuance of U.S. Patent for Proprietary Excipients in SQore Platform - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/comera-life-sciences-announces-issuance-of-u-s-patent-for-proprietary-excipients-in-sqore-platform\/","og_locale":"en_US","og_type":"article","og_title":"Comera Life Sciences Announces Issuance of U.S. Patent for Proprietary Excipients in SQore Platform - Pharma Trend","og_description":"WOBURN, Mass.–(BUSINESS WIRE)–Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, expanded its patent portfolio with the issuance of U.S. Patent No. 11,357,857 (the \u2018857 patent), which provides Comera exclusive rights pertaining to certain excipients in its SQore\u2122 ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/comera-life-sciences-announces-issuance-of-u-s-patent-for-proprietary-excipients-in-sqore-platform\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-22T12:01:44+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220621006060\/en\/1493063\/21\/comera_logo_rgb.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/comera-life-sciences-announces-issuance-of-u-s-patent-for-proprietary-excipients-in-sqore-platform\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/comera-life-sciences-announces-issuance-of-u-s-patent-for-proprietary-excipients-in-sqore-platform\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Comera Life Sciences Announces Issuance of U.S. Patent for Proprietary Excipients in SQore Platform","datePublished":"2022-06-22T12:01:44+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/comera-life-sciences-announces-issuance-of-u-s-patent-for-proprietary-excipients-in-sqore-platform\/"},"wordCount":1029,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/comera-life-sciences-announces-issuance-of-u-s-patent-for-proprietary-excipients-in-sqore-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220621006060\/en\/1493063\/21\/comera_logo_rgb.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/comera-life-sciences-announces-issuance-of-u-s-patent-for-proprietary-excipients-in-sqore-platform\/","url":"https:\/\/pharma-trend.com\/en\/comera-life-sciences-announces-issuance-of-u-s-patent-for-proprietary-excipients-in-sqore-platform\/","name":"Comera Life Sciences Announces Issuance of U.S. Patent for Proprietary Excipients in SQore Platform - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/comera-life-sciences-announces-issuance-of-u-s-patent-for-proprietary-excipients-in-sqore-platform\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/comera-life-sciences-announces-issuance-of-u-s-patent-for-proprietary-excipients-in-sqore-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220621006060\/en\/1493063\/21\/comera_logo_rgb.jpg","datePublished":"2022-06-22T12:01:44+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/comera-life-sciences-announces-issuance-of-u-s-patent-for-proprietary-excipients-in-sqore-platform\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/comera-life-sciences-announces-issuance-of-u-s-patent-for-proprietary-excipients-in-sqore-platform\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/comera-life-sciences-announces-issuance-of-u-s-patent-for-proprietary-excipients-in-sqore-platform\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220621006060\/en\/1493063\/21\/comera_logo_rgb.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220621006060\/en\/1493063\/21\/comera_logo_rgb.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/comera-life-sciences-announces-issuance-of-u-s-patent-for-proprietary-excipients-in-sqore-platform\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Comera Life Sciences Announces Issuance of U.S. Patent for Proprietary Excipients in SQore Platform"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45355","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=45355"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45355\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=45355"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=45355"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=45355"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}